PT2438087T - Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório - Google Patents
Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratórioInfo
- Publication number
- PT2438087T PT2438087T PT107244972T PT10724497T PT2438087T PT 2438087 T PT2438087 T PT 2438087T PT 107244972 T PT107244972 T PT 107244972T PT 10724497 T PT10724497 T PT 10724497T PT 2438087 T PT2438087 T PT 2438087T
- Authority
- PT
- Portugal
- Prior art keywords
- hrsv
- prevention
- treatment
- syncytial virus
- tract infections
- Prior art date
Links
- 241000711920 Human orthopneumovirus Species 0.000 title 1
- 206010057190 Respiratory tract infections Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18439609P | 2009-06-05 | 2009-06-05 | |
US26501409P | 2009-11-30 | 2009-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2438087T true PT2438087T (pt) | 2017-08-04 |
Family
ID=42333502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT107244972T PT2438087T (pt) | 2009-06-05 | 2010-06-07 | Construções de nanobody trivalentes de vírus sincicial respiratório humano (hrsv) para a prevenção e/ou tratamento de infeções do trato respiratório |
Country Status (25)
Country | Link |
---|---|
US (3) | US8945567B2 (pt) |
EP (2) | EP3205670A1 (pt) |
JP (2) | JP6081196B2 (pt) |
KR (1) | KR101852204B1 (pt) |
CN (2) | CN102459332B (pt) |
AU (1) | AU2010255638B2 (pt) |
BR (1) | BRPI1010830A2 (pt) |
CA (1) | CA2764398A1 (pt) |
CY (1) | CY1119265T1 (pt) |
DK (1) | DK2438087T3 (pt) |
ES (1) | ES2643034T3 (pt) |
HR (1) | HRP20171194T1 (pt) |
HU (1) | HUE035773T2 (pt) |
IL (1) | IL216341A0 (pt) |
LT (1) | LT2438087T (pt) |
MX (1) | MX340541B (pt) |
NZ (1) | NZ597314A (pt) |
PH (1) | PH12019500644A1 (pt) |
PL (1) | PL2438087T3 (pt) |
PT (1) | PT2438087T (pt) |
RU (2) | RU2016103067A (pt) |
SG (1) | SG176095A1 (pt) |
SI (1) | SI2438087T1 (pt) |
WO (1) | WO2010139808A2 (pt) |
ZA (1) | ZA201108892B (pt) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LT2285408T (lt) | 2008-06-05 | 2019-01-25 | Ablynx N.V. | Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui |
CN102459332B (zh) | 2009-06-05 | 2015-08-19 | 埃博灵克斯股份有限公司 | 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体 |
EP2507262A1 (en) * | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
WO2011073180A1 (en) | 2009-12-14 | 2011-06-23 | Ablynx N.V. | Single variable domain antibodies against ox40l, constructs and therapeutic use |
CN102753148B (zh) | 2010-02-11 | 2018-01-26 | 埃博灵克斯股份有限公司 | 用于制备气雾剂的方法和组合物 |
DK2632946T3 (en) | 2010-10-29 | 2018-03-12 | Ablynx Nv | PROCEDURE FOR MANUFACTURING VARIABLE IMMUNGLOBULIN SINGLE DOMAINS |
EP2707382B1 (en) | 2011-05-09 | 2019-07-17 | Ablynx NV | Method for the production of immunoglobulin single variable domains |
US11339208B1 (en) | 2012-05-31 | 2022-05-24 | United States Of America As Represented By The Secretary Of The Air Force | Camelidae single-domain antibodies against Yersinia pestis and methods of use |
WO2014159940A1 (en) | 2013-03-14 | 2014-10-02 | Macrogenics, Inc. | Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor |
JP6485817B2 (ja) | 2013-08-21 | 2019-03-20 | ヤンセン バイオファーマ インク. | 抗ウイルス化合物 |
CA2957017A1 (en) * | 2014-08-05 | 2016-02-11 | Alios Biopharma, Inc. | Combination therapy for treating a paramyxovirus |
US10717778B2 (en) | 2014-09-29 | 2020-07-21 | Duke University | Bispecific molecules comprising an HIV-1 envelope targeting arm |
AU2015329935B2 (en) | 2014-10-10 | 2019-09-19 | Ablynx N.V. | Inhalation device for use in aerosol therapy of respiratory diseases |
KR20170093120A (ko) * | 2014-10-10 | 2017-08-14 | 아블린쓰 엔.브이. | Rsv 감염의 치료 방법 |
MA41614A (fr) | 2015-02-25 | 2018-01-02 | Alios Biopharma Inc | Composés antiviraux |
EP3124042A1 (en) * | 2015-07-28 | 2017-02-01 | VIB, vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
EP3313432A1 (en) | 2015-06-18 | 2018-05-02 | VIB vzw | Immunoglobulin single variable domain antibody against rsv prefusion f protein |
CA3022697A1 (en) | 2016-05-02 | 2017-11-09 | Ablynx Nv | Treatment of rsv infection |
RU2765809C2 (ru) | 2016-06-23 | 2022-02-03 | Аблинкс Н.В. | Усовершенствованные фармакокинетические анализы для одиночных вариабельных доменов иммуноглобулина |
CN106279410B (zh) * | 2016-09-29 | 2019-08-20 | 华南理工大学 | 一种二型登革热病毒ns1蛋白多价纳米抗体及制备方法 |
US11312761B2 (en) | 2016-10-21 | 2022-04-26 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
US11479600B2 (en) | 2016-10-21 | 2022-10-25 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
US11485775B2 (en) | 2016-10-21 | 2022-11-01 | Adimab, Llc | Anti-respiratory syncytial virus antibodies, and methods of their generation and use |
WO2018099968A1 (en) | 2016-11-29 | 2018-06-07 | Ablynx N.V. | Treatment of infection by respiratory syncytial virus (rsv) |
AU2018346978B2 (en) | 2017-10-13 | 2024-02-15 | Mapp Biopharmaceutical, Inc. | Anti-respiratory syncytial virus antibodies, methods of their generation and use |
JP7123607B2 (ja) * | 2018-04-09 | 2022-08-23 | シャープ株式会社 | ユーザ装置、制御装置、及び通信制御方法 |
MA55615A (fr) | 2019-04-10 | 2022-02-16 | Regeneron Pharma | Anticorps humains qui se lient au ret et leurs procédés d'utilisation |
CN111748571B (zh) * | 2019-10-11 | 2022-05-03 | 浙江禾霖生物科技有限公司 | 一种将枯草芽孢杆菌工程化为生产纳米抗体的多功能稳定平台的方法 |
PE20221865A1 (es) | 2019-11-25 | 2022-12-02 | Mabloc Llc | Anticuerpos contra el virus de la fiebre amarilla y metodos de su generacion y uso |
US20210230248A1 (en) * | 2020-01-25 | 2021-07-29 | Jun Chen | Multivalent pharmacophores for high avidity and overexpressed-target specific binding and uses thereof |
CN116693673B (zh) * | 2023-07-26 | 2023-10-20 | 中国人民解放军军事科学院军事医学研究院 | 广谱抗SARS和SARS-CoV-2的纳米抗体、多价纳米抗体及其应用 |
Family Cites Families (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1120945A (en) | 1964-08-11 | 1968-07-24 | Fisons Pharmaceuticals Ltd | Applicator in combination with a pressurised aerosol dispensing container |
ATE189526T1 (de) | 1988-10-28 | 2000-02-15 | Genentech Inc | Verfahren zum nachweis von aktiven domänen und aminosäureresten in polypeptiden und hormonvarianten |
WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
DE69112207T2 (de) | 1990-04-05 | 1996-03-28 | Roberto Crea | "walk-through"-mutagenese. |
AU665025B2 (en) | 1991-09-23 | 1995-12-14 | Cambridge Antibody Technology Limited | Production of chimeric antibodies - a combinatorial approach |
DE69334095T2 (de) | 1992-07-17 | 2007-04-12 | Dana-Farber Cancer Institute, Boston | Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen |
ES2162823T5 (es) | 1992-08-21 | 2010-08-09 | Vrije Universiteit Brussel | Inmunoglobulinas desprovistas de cadenas ligeras. |
JP3626187B2 (ja) | 1993-06-07 | 2005-03-02 | バイカル インコーポレイテッド | 遺伝子治療に適するプラスミド |
CA2162878A1 (en) | 1993-06-09 | 1994-12-22 | Leon Gerardus Joseph Frenken | Process for producing fusion proteins comprising scfv fragments by a transformed mould |
US6091639A (en) | 1993-08-27 | 2000-07-18 | Kabushiki Kaisha Toshiba | Non-volatile semiconductor memory device and data programming method |
DE69435112D1 (de) | 1993-09-10 | 2008-08-21 | Univ Columbia | Verwendung von grünem fluoreszenzprotein |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
WO1995022618A1 (en) | 1994-02-22 | 1995-08-24 | Dana-Farber Cancer Institute | Nucleic acid delivery system, method of synthesis and uses thereof |
US5625048A (en) | 1994-11-10 | 1997-04-29 | The Regents Of The University Of California | Modified green fluorescent proteins |
EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
US5693492A (en) | 1995-05-05 | 1997-12-02 | Merck & Co., Inc. | DNA encoding glutamate gated chloride channels |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
WO1997000957A1 (en) | 1995-06-23 | 1997-01-09 | President And Fellows Of Harvard College | Transcriptional regulation of genes encoding vascular endothelial growth factor receptors |
JP3535177B2 (ja) | 1995-09-22 | 2004-06-07 | バイオイメージ・アクティーゼルスカブ | 緑色蛍光性タンパクであるgfpの新規な変種 |
US6027881A (en) | 1996-05-08 | 2000-02-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutant Aequorea victoria fluorescent proteins having increased cellular fluorescence |
US6020182A (en) * | 1996-07-12 | 2000-02-01 | Connaught Laboratories Limited | Subunit respiratory syncytial virus vaccine preparation |
US6124128A (en) | 1996-08-16 | 2000-09-26 | The Regents Of The University Of California | Long wavelength engineered fluorescent proteins |
CA2270288A1 (en) * | 1996-11-01 | 1998-05-14 | Smithkline Beecham Corporation | Human monoclonal antibodies |
WO1998021355A1 (en) | 1996-11-15 | 1998-05-22 | Life Technologies, Inc. | Mutants of green fluorescent protein |
EP1027073A2 (en) | 1996-11-19 | 2000-08-16 | Sangstat Medical Corporation | Enhanced effects for hapten conjugated therapeutics |
US7122636B1 (en) | 1997-02-21 | 2006-10-17 | Genentech, Inc. | Antibody fragment-polymer conjugates and uses of same |
US6329516B1 (en) | 1997-04-28 | 2001-12-11 | Fmc Corporation | Lepidopteran GABA-gated chloride channels |
FR2766826B1 (fr) | 1997-08-04 | 2001-05-18 | Pasteur Institut | Vecteurs derives d'anticorps pour le transfert de substances dans les cellules |
JP2003525016A (ja) | 1998-02-19 | 2003-08-26 | エクサイト セラピーズ, インコーポレイテッド | リンパ球活性化を調節するための組成物および方法 |
GB9824632D0 (en) | 1998-11-10 | 1999-01-06 | Celltech Therapeutics Ltd | Biological compounds |
AU779162B2 (en) | 1999-02-05 | 2005-01-06 | Rijksuniversiteit Leiden | Method of modulating metabolite biosynthesis in recombinant cells |
EP1169453A1 (en) | 1999-04-22 | 2002-01-09 | Unilever Plc | Inhibition of viral infection using monovalent antigen-binding proteins |
AR030019A1 (es) | 1999-05-18 | 2003-08-13 | Smithkline Beecham Corp | Anticuerpos monoclonales humanos y fragmentos funcionales del mismo, un procedimiento para su produccion, composiciones farmaceuticas que los comprenden, una molecula aislada de acido nucleico, un plasmido recombinante, una celula hospedante y el uso de dichos anticuerpos para la manufactura de un m |
WO2001009300A2 (en) | 1999-08-02 | 2001-02-08 | Keygene N.V. | Method for generating cgmmv resistant plants, genetic constructs, and obtained cgmmv-resistant plants |
GB9922124D0 (en) | 1999-09-17 | 1999-11-17 | Pfizer Ltd | Phosphodiesterase enzymes |
US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
DE19955408A1 (de) | 1999-11-18 | 2001-05-23 | Bayer Ag | GABA-B-Rezeptoren |
JP2003518075A (ja) | 1999-12-24 | 2003-06-03 | ジェネンテック・インコーポレーテッド | 生理活性化合物の消失半減期延長のための方法及び組成物 |
US6741957B1 (en) | 2000-07-21 | 2004-05-25 | Daimlerchrysler Corporation | Analytical tire model for vehicle durability and ride comfort analysis |
US6818216B2 (en) | 2000-11-28 | 2004-11-16 | Medimmune, Inc. | Anti-RSV antibodies |
US7054297B1 (en) | 2000-12-28 | 2006-05-30 | Cisco Technology, Inc. | Distribution of packets to high data rate communications devices using multicast protocols |
EP2706116A1 (en) | 2001-01-17 | 2014-03-12 | Emergent Product Development Seattle, LLC | Binding domain-immunoglobulin fusion proteins |
US7829084B2 (en) | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
WO2002076489A1 (en) | 2001-03-09 | 2002-10-03 | Dyax Corp. | Serum albumin binding moieties |
US20060073141A1 (en) | 2001-06-28 | 2006-04-06 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
AU2002319402B2 (en) | 2001-06-28 | 2008-09-11 | Domantis Limited | Dual-specific ligand and its use |
EP1425694A2 (en) | 2001-08-03 | 2004-06-09 | Medical Research Council | Method of identifying a consensus sequence for intracellular antibodies |
FR2829940A1 (fr) | 2001-09-27 | 2003-03-28 | Synt Em | Compositions pour la vectorisation d'anticorps a travers la barriere hematoencephalique et leur utilisation pour le diagnostic ou le traitement des maladies du systeme nerveux central |
KR100599789B1 (ko) | 2001-12-03 | 2006-07-12 | 삼성에스디아이 주식회사 | 방열효율이 향상된 플라즈마 디스플레이 장치 및 그 제조방법 |
US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
RU2319505C2 (ru) | 2001-12-18 | 2008-03-20 | Иннодженетикс Н.В. | Очищенные оболочечные белки вируса гепатита с для диагностического и терапевтического применения |
CN1305905C (zh) | 2002-03-22 | 2007-03-21 | Aprogen株式会社 | 人源化抗体及其制备方法 |
US7132100B2 (en) * | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
US7004940B2 (en) | 2002-10-10 | 2006-02-28 | Ethicon, Inc. | Devices for performing thermal ablation having movable ultrasound transducers |
AU2003284891A1 (en) | 2002-10-23 | 2004-05-13 | Ludwig Institute For Cancer Research | A34 and a33-like 3 dna, proteins, antibodies thereto and methods of treatment using same |
EP1558650A2 (en) | 2002-11-08 | 2005-08-03 | Ablynx N.V. | Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders |
CA2505325C (en) | 2002-11-08 | 2014-02-25 | Ablynx N.V. | Stabilized single domain antibodies |
WO2010081856A1 (en) | 2009-01-14 | 2010-07-22 | Ablynx Nv | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
GB0230203D0 (en) | 2002-12-27 | 2003-02-05 | Domantis Ltd | Fc fusion |
ATE444984T1 (de) | 2002-12-31 | 2009-10-15 | Nektar Therapeutics Al Corp | Hydrolysestabile maleimidendgruppen-enthaltende polymere |
WO2004062551A2 (en) | 2003-01-10 | 2004-07-29 | Ablynx N.V. | RECOMBINANT VHH SINGLE DOMAIN ANTIBODY FROM CAMELIDAE AGAINST VON WILLEBRAND FACTOR (vWF) OR AGAINST COLLAGEN |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US7070786B2 (en) | 2003-06-06 | 2006-07-04 | Centocor, Inc. | RSV proteins, antibodies, compositions, methods and uses |
JP4791960B2 (ja) | 2003-06-27 | 2011-10-12 | バイオレン,インク. | ルックスルー突然変異誘発 |
CN1845938B (zh) | 2003-06-30 | 2010-05-26 | 杜门蒂斯有限公司 | 多肽 |
JP2008530626A (ja) | 2003-06-30 | 2008-08-07 | シーメンス アクチエンゲゼルシヤフト | マイクロコンピュータにおけるプログラムの実行を監視する方法 |
CA2535550A1 (en) | 2003-08-12 | 2005-03-03 | William M. Yarbrough | Treatment for acne vulgaris and method of use |
EP1512696A1 (en) | 2003-08-14 | 2005-03-09 | Diatos | Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei |
ES2646560T3 (es) | 2004-01-20 | 2017-12-14 | Merus N.V. | Mezclas de proteínas de unión |
EP1720908A2 (en) * | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
US7207410B2 (en) | 2004-04-29 | 2007-04-24 | Daimlerchrysler Corporation | Apparatus and method for enhanced impact sensing |
AU2005265163B2 (en) | 2004-06-18 | 2009-10-01 | Ambrx, Inc. | Novel antigen-binding polypeptides and their uses |
JP4939410B2 (ja) | 2004-07-06 | 2012-05-23 | バイオレン,インク. | 強化された特性を持つ変性ポリペプチドを発生させるためのルックスルー変異誘発 |
US7180370B2 (en) | 2004-09-01 | 2007-02-20 | Micron Technology, Inc. | CMOS amplifiers with frequency compensating capacitors |
US7563443B2 (en) | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
EP3073267A1 (en) | 2004-09-21 | 2016-09-28 | Medimmune, Inc. | Antibodies against and methods for producing vaccines for respiratory syncytial virus |
KR20070084170A (ko) | 2004-10-13 | 2007-08-24 | 아블린쓰 엔.브이. | 알쯔하이머병 등의 퇴행성 신경 질환의 치료 및 진단을위한 단일 도메인 카멜리드 항-아밀로이드 베타 항체 및이를 포함하는 폴리펩타이드 |
TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
US20060115485A1 (en) | 2004-10-29 | 2006-06-01 | Medimmune, Inc. | Methods of preventing and treating RSV infections and related conditions |
BRPI0518622A2 (pt) * | 2004-12-02 | 2008-12-02 | Domantis Ltd | usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento |
EP1874824A4 (en) * | 2005-04-06 | 2009-12-30 | Ibc Pharmaceuticals Inc | METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF |
US20060228367A1 (en) | 2005-04-08 | 2006-10-12 | Medimmune, Inc. | Antibodies against mammalian metapneumovirus |
HUE045710T2 (hu) | 2005-05-18 | 2020-01-28 | Ablynx Nv | Javított, alfa tumor nekrózis faktor elleni nanobodies |
WO2008020079A1 (en) | 2006-08-18 | 2008-02-21 | Ablynx N.V. | Amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of deseases and disorders associated with il-6-mediated signalling |
AU2007293614A1 (en) | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
WO2008043821A1 (en) | 2006-10-11 | 2008-04-17 | Ablynx N. V. | Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the ph, compounds comprising the same, and use thereof |
US20100034194A1 (en) | 2006-10-11 | 2010-02-11 | Siemens Communications Inc. | Eliminating unreachable subscribers in voice-over-ip networks |
AU2007310838A1 (en) | 2006-10-27 | 2008-05-02 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
CA2671581A1 (en) | 2006-12-05 | 2008-06-12 | Ablynx N.V. | Peptides capable of binding to serum proteins |
WO2008077945A2 (en) | 2006-12-22 | 2008-07-03 | Ablynx N.V. | Anti-chemokine (ccl2, ccl3, ccl5, cxcl11, cxcl12) single-domain antibodies |
US10214588B2 (en) | 2007-07-03 | 2019-02-26 | Ablynx N.V. | Providing improved immunoglobulin sequences by mutating CDR and/or FR positions |
AU2008328779B2 (en) | 2007-11-27 | 2014-06-05 | Ablynx N.V. | Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors |
EP2096121A1 (en) | 2008-02-29 | 2009-09-02 | Institut Pasteur Of Shanghai | Antiviral peptides comprising lipid attachment signals and methods of use |
LT2285408T (lt) | 2008-06-05 | 2019-01-25 | Ablynx N.V. | Aminorūgščių sekos, nukreiptos prieš viruso apvalkalo baltymus, ir tokias sekas turintys polipeptidai, skirti virusinių ligų gydymui |
EP3828201A1 (en) | 2009-04-30 | 2021-06-02 | Ablynx N.V. | Method for the production of domain antibodies |
CN102459332B (zh) | 2009-06-05 | 2015-08-19 | 埃博灵克斯股份有限公司 | 用于预防和/或治疗呼吸道感染的单价、二价和三价抗人呼吸道合胞病毒(hrsv)纳米抗体构建体 |
EP2507262A1 (en) | 2009-11-30 | 2012-10-10 | Ablynx N.V. | Improved amino acid sequences directed against human respiratory syncytial virus (hrsv) and polypeptides comprising the same for the prevention and/or treatment of respiratory tract infections |
-
2010
- 2010-06-07 CN CN201080024764.4A patent/CN102459332B/zh not_active Expired - Fee Related
- 2010-06-07 SI SI201031523T patent/SI2438087T1/sl unknown
- 2010-06-07 AU AU2010255638A patent/AU2010255638B2/en not_active Ceased
- 2010-06-07 ES ES10724497.2T patent/ES2643034T3/es active Active
- 2010-06-07 HU HUE10724497A patent/HUE035773T2/en unknown
- 2010-06-07 JP JP2012513641A patent/JP6081196B2/ja not_active Expired - Fee Related
- 2010-06-07 DK DK10724497.2T patent/DK2438087T3/en active
- 2010-06-07 LT LTEP10724497.2T patent/LT2438087T/lt unknown
- 2010-06-07 US US13/375,357 patent/US8945567B2/en active Active
- 2010-06-07 BR BRPI1010830A patent/BRPI1010830A2/pt not_active IP Right Cessation
- 2010-06-07 EP EP17162779.7A patent/EP3205670A1/en not_active Withdrawn
- 2010-06-07 MX MX2011013013A patent/MX340541B/es active IP Right Grant
- 2010-06-07 CA CA2764398A patent/CA2764398A1/en not_active Abandoned
- 2010-06-07 SG SG2011084274A patent/SG176095A1/en unknown
- 2010-06-07 KR KR1020127000199A patent/KR101852204B1/ko active IP Right Grant
- 2010-06-07 RU RU2016103067A patent/RU2016103067A/ru unknown
- 2010-06-07 PL PL10724497T patent/PL2438087T3/pl unknown
- 2010-06-07 WO PCT/EP2010/057921 patent/WO2010139808A2/en active Application Filing
- 2010-06-07 CN CN201510509040.3A patent/CN105061592A/zh active Pending
- 2010-06-07 NZ NZ597314A patent/NZ597314A/xx not_active IP Right Cessation
- 2010-06-07 RU RU2011153239/10A patent/RU2577134C2/ru active
- 2010-06-07 EP EP10724497.2A patent/EP2438087B1/en active Active
- 2010-06-07 PT PT107244972T patent/PT2438087T/pt unknown
-
2011
- 2011-11-02 ZA ZA2011/08892A patent/ZA201108892B/en unknown
- 2011-11-14 IL IL216341A patent/IL216341A0/en unknown
-
2014
- 2014-09-29 US US14/499,772 patent/US9803001B2/en active Active
-
2017
- 2017-01-18 JP JP2017006690A patent/JP6677659B2/ja not_active Expired - Fee Related
- 2017-08-02 HR HRP20171194TT patent/HRP20171194T1/hr unknown
- 2017-08-08 CY CY20171100847T patent/CY1119265T1/el unknown
- 2017-09-22 US US15/712,247 patent/US11028151B2/en active Active
-
2019
- 2019-03-25 PH PH12019500644A patent/PH12019500644A1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL2438087T3 (pl) | Triwalentne konstrukty nanociał przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (hRSV) do zapobiegania i/lub leczenia zakażeń dróg oddechowych | |
HK1172350A1 (zh) | 針對人呼吸道合胞病毒 的抗體以及使用方法 | |
HK1199607A1 (en) | Human milk oligosaccharides for preventing injury and or promoting healing of the gastrointestinal tract | |
HK1196131A1 (zh) | 用於治療或預防呼吸道合胞病毒疾病的化合物 | |
ZA201304638B (en) | Composition for use in the prevention and /or treatment of skin condition and skin diseases. | |
IL227193B (en) | Plant extracts for the treatment and prevention of infections | |
EP2349140A4 (en) | DEVICES, SYSTEMS AND METHODS FOR TREATING SLEEP APNEA | |
IL200330A0 (en) | Recombinant antibodies for treatment of respiratory syncytial virus infections | |
PL2521562T3 (pl) | Ev576 do zastosowania w leczeniu zakażeń wirusowych dróg oddechowych | |
ZA201209289B (en) | Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract | |
GB2496794B (en) | Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract | |
EP2427061A4 (en) | GALLIUM FORMULATION FOR THE TREATMENT AND PROPHYLAXIS OF INFECTION DISEASES | |
EP2651439A4 (en) | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HUMAN ADENOVIRUS 36 INFECTION | |
IL216967B (en) | The history of 17-hydroxy-17-pentafluoroethyl-astra-9,4 (10)-diene-11-aryl and their use for the treatment of diseases | |
GB2496800B (en) | Combination pharmaceutical composition and methods of treating diseases or conditions associated with respiratory disease or condition | |
EP2521554A4 (en) | SUBSTANCES AND METHODS FOR THE PREVENTION AND TREATMENT OF VIRAL INFECTIONS | |
HK1197058A1 (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
EP2222258A4 (en) | SYSTEMS AND METHOD FOR HEAT TREATMENT OF BODY TISSUE | |
EP2361317A4 (en) | USE OF EIF3M FOR THE DIAGNOSIS AND TREATMENT OF CANCER | |
PL2895180T3 (pl) | Kompozycja do zapobiegania i leczenia ostrych i nawracających zakażeń dróg moczowych | |
SI2508192T1 (sl) | Sredstvo za zdravljenje in preprečevanje bolezni moškega urogenitalnega sistema | |
HK1188565A1 (en) | Diarylpyridazinone derivatives, preparation thereof, and use thereof for the treatment of humans | |
EP2160191A4 (en) | SUPPRESSION OF VIRUSES INVOLVED IN A DISEASE OR RESPIRATORY INFECTION | |
SI2315580T1 (sl) | Farmacevtski pripravki in postopki za zdravljenjeinfekcij respiratornega trakta | |
ZA201400442B (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease |